MX2019000508A - Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1). - Google Patents

Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1).

Info

Publication number
MX2019000508A
MX2019000508A MX2019000508A MX2019000508A MX2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A
Authority
MX
Mexico
Prior art keywords
imaging
radioligands
ido1 enzyme
ido1
enzyme
Prior art date
Application number
MX2019000508A
Other languages
English (en)
Spanish (es)
Inventor
Huang Audris
Aaron Balog James
j donnelly David
Lee COLE Erin
Charles BURRELL Richard
A Turley Wesley
J Allentoff Alban
Arthur WALLACE Michael
Skinbjerg Mette
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2019000508A publication Critical patent/MX2019000508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2019000508A 2016-07-19 2017-07-18 Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1). MX2019000508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (1)

Publication Number Publication Date
MX2019000508A true MX2019000508A (es) 2019-03-28

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000508A MX2019000508A (es) 2016-07-19 2017-07-18 Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1).

Country Status (12)

Country Link
US (2) US20190282714A1 (enExample)
EP (1) EP3487516A1 (enExample)
JP (1) JP6987840B2 (enExample)
KR (1) KR102513886B1 (enExample)
CN (1) CN109475594A (enExample)
AU (1) AU2017298262B2 (enExample)
BR (1) BR112019000499A2 (enExample)
EA (1) EA039877B1 (enExample)
IL (1) IL264187B (enExample)
MX (1) MX2019000508A (enExample)
SG (1) SG11201900336YA (enExample)
WO (1) WO2018017529A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3503916A1 (en) * 2016-08-26 2019-07-03 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019006292A1 (en) * 2017-06-30 2019-01-03 Bristol-Myers Squibb Company SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF
JP2021510044A (ja) * 2017-11-21 2021-04-08 オッポ広東移動通信有限公司Guangdong Oppo Mobile Telecommunications Corp., Ltd. 情報伝送方法、ネットワークデバイス及び端末デバイス
WO2019111107A1 (en) * 2017-12-05 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (zh) * 2007-11-09 2008-05-21 中山大学 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用
CN102781316B (zh) * 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
US20220305144A1 (en) 2022-09-29
WO2018017529A1 (en) 2018-01-25
KR20190030727A (ko) 2019-03-22
JP6987840B2 (ja) 2022-01-05
JP2019527225A (ja) 2019-09-26
SG11201900336YA (en) 2019-02-27
EP3487516A1 (en) 2019-05-29
CA3031079A1 (en) 2018-01-25
US20190282714A1 (en) 2019-09-19
IL264187A (en) 2019-02-28
CN109475594A (zh) 2019-03-15
AU2017298262A1 (en) 2019-03-07
IL264187B (en) 2021-06-30
EA201990198A1 (ru) 2019-06-28
AU2017298262B2 (en) 2024-07-18
BR112019000499A2 (pt) 2019-04-24
EA039877B1 (ru) 2022-03-23
KR102513886B1 (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
ZA201906822B (en) Indole ahr inhibitors and uses thereof
ZA201903984B (en) Methods of using thermostable serine proteases
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
PH12018500397A1 (en) Compounds and compositions useful for treating disorders related to ntrk
ZA201702071B (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
SG10201902813XA (en) Methods and materials for biosynthesis of mogroside compounds
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
SG10202102897PA (en) Compositions and methods for the depletion of cd137+ cells
EA201990198A1 (ru) Радиолиганды для визуализации фермента ido1
EP4116293A3 (en) Rho kinase inhibitors
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX375892B (es) Composición que comprende sal de glutamato de acilo como tensoactivo principal o tensoactivo principal aniónico
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
MY182924A (en) Enzyme compositions and uses thereof
MX2018007083A (es) Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031.
WO2016079110A3 (en) Use of enzyme for cleaning
EP3337805A4 (en) INHIBITORS OF THE TEC KINASE ENZYM FAMILY
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3341112A4 (en) METHOD AND COMPOSITIONS FOR PROTEIN CLEANING AND ENZYME REACTION
MX388832B (es) Deteccion especifica de isoformas de clusterina.